New drug CS-1103 takes first step toward fighting meth abuse
NCT ID NCT06316973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety of a new drug called CS-1103 in 32 healthy adults. Researchers gave single doses by IV to see if it causes side effects and how the body processes it. The goal is to gather basic safety information before testing it in people with methamphetamine problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CS-1103
- What this could lead to
- If safe, this could lead to further studies testing CS-1103 as a treatment for methamphetamine abuse or overdose.
- What could go wrong
- This is a very early, small study in healthy people, not those with substance use disorders. It only checks safety and dosing, not whether the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE ABUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Vince Clinical Research
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a family talk program shield teens from substance use?
- Can online training equip therapists to tackle PTSD and addiction?
- Rewriting the story: can a talking therapy help people shed self-stigma and reclaim their identity?
- Can a once-weekly antibiotic help people with opioid use disorder beat serious infections at home?
- Telehealth counseling may break down barriers to opioid treatment for veterans